Overview

Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
A randomized, placebo-controlled, double-blind clinical trial of effect of allopurinol or febuxostat to prevent contrast induced acute kidney injury (CI-AKI)
Phase:
Phase 2
Details
Lead Sponsor:
Instituto Nacional de Cardiologia Ignacio Chavez
Collaborators:
Armando Vázquez Rangel
Salvador López Gil
Treatments:
Allopurinol
Febuxostat